Kan ppp utvecklas till generaliserad pustulös psoriasis

Pustular psoriasis is a form of psoriasis characterized by neutrophil-containing pustules on an erythematous background [ 1 ].

Psoriasis ansikte

This article reviews the clinical features of PPP and GPP, in addition to recent developments in our understanding of the genetics and immunology of the conditions. This article aims to help doctors who treat skin conditions dermatologists to identify and treat people with pustular psoriasis. Nonetheless, recent advances in understanding of the pathogenesis of pustular psoriasis have provided insights into possible targeted therapies, including biologic therapies.

The site is secure. Treatment of pustular psoriasis is generally determined by the extent and severity of disease, and recent years have seen an increasing use of newer agents, including biologic therapies. The online version contains supplementary material available at Pustular psoriasis is a skin condition where people develop small pus-filled blisters on their skin.

Doctors often use treatments that have been shown to work in plaque psoriasis, which is the most common type of psoriasis, to treat people with GPP and PPP. Researchers are working on developing new effective treatments for pustular psoriasis that may work more rapidly and have fewer side effects. Further research into agents acting on the IL pathway and other targeted therapies has the potential to transform the future treatment of patients with pustular psoriasis.

The condition has two distinct subtypes: localized disease occurring on the palms and soles, known as palmoplantar pustulosis PPP; also called palmoplantar pustular psoriasis , and generalized pustular psoriasis GPP. The involvement of the fingers, toes, and nails is defined as a separate localized variant, acrodermatitis continua of Hallopeau, which is now thought to be a subset of PPP.

Pustular psoriasis generally follows a relapsing and remitting course, requiring long-term disease management. These are expected to be available in the next few years. This is called palmoplantar pustulosis PPP for short. Around 5—12 in every 10, people worldwide develop PPP. GPP is even rarer, affecting only 2—7 out of every 1 million people.

Other relevant literature was obtained on the basis of personal knowledge and experience of the authors. In addition to being relatively uncommon, these conditions are challenging to treat. At present, there is limited evidence on which to base treatment recommendations for pustular psoriasis, partly due to the less common nature of the condition, and current therapies are based on existing treatments for plaque psoriasis [ 6 , 7 ].

The emerging drugs for pustular psoriasis offer the possibility of rapid and effective treatment with lower toxicities than existing therapies. The condition presents with pustules on an erythematous background and has two distinct subtypes: localized disease on the palms and soles, called palmoplantar pustulosis PPP , and generalized pustular psoriasis GPP.

The involvement of the fingers, toes, and nails is defined as a separate localized variant, acrodermatitis continua of Hallopeau, and is now thought to be a subset of PPP. The rarity of pustular psoriasis frequently makes the correct diagnosis problematic. The Medline database was searched via PubMed to retrieve relevant articles on generalized pustular psoriasis, palmoplantar pustulosis, and pustular psoriasis published between and limits: humans, English language.

Another type of pustular psoriasis can affect most of the body called generalized pustular psoriasis GPP for short. However, there remains a need for treatments with high, sustained efficacy and a rapid onset of action in pustular psoriasis. Pustular psoriasis is an unusual form of psoriasis that frequently presents clinical challenges for dermatologists.

Recent advances in understanding of the pathogenesis of pustular psoriasis have provided insights into potential therapies. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. This article reviews the clinical features of PPP and GPP, and current understanding of the genetics and immunopathology of these conditions; it also provides an update on emerging treatments.

Data sharing is not applicable to this article as no data sets were generated or analyzed during the current study. Federal government websites often end in.

An update on potential new treatments is also included. This article is published with digital features, including an infographic, to facilitate understanding of the article.

Pustulös psoriasis

In addition, treatment is limited by a relative lack of evidence-based therapeutic options. Pustular psoriasis is generally considered to be idiopathic, although genetic factors do play a role in disease susceptibility. Manual assessment of retrieved references was used as the basis for a narrative overview of the literature. Current management is often based on existing therapies for standard plaque psoriasis.

It is distinct from the more common plaque psoriasis—not only clinically but also histologically and genetically [ 2 ]. PPP is the most common variant of pustular psoriasis; it has a reported prevalence of 0. In addition, the use of tumor necrosis factor alpha TNFα inhibitors may occasionally cause paradoxical triggering of immune-mediated skin diseases, including pustular psoriasis [ 3 — 5 ]. Precipitating and exacerbating factors include smoking, infections, withdrawal from medications e.